3745results about "Cell dissociation methods" patented technology

The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom.

Cells derived from postpartum tissue and methods for their isolation and induction to differentiate to cells of a chondrogenic or osteogenic phenotype are provided by the invention. The invention further provides cultures and compositions of the postpartum-derived cells and products related thereto. The postpartum-derived cells of the invention and products related thereto have a plethora of uses, including but not limited to research, diagnostic, and therapeutic applications, for example, in the treatment of bone and cartilage conditions.

A method of collecting embryonic-like stem cells from a placenta which has been treated to remove residual cord blood by perfusing the drained placenta with an anticoagulant solution to flush out residual cells, collecting the residual cells and perfusion liquid from the drained placenta, and separating the embryonic-like cells from the residual cells and perfusion liquid. Exogenous cells can be propagated in the placental bioreactor and bioactive molecules collected therefrom.

Cells derived from postpartum tissue such as the umbilical cord and placenta, and methods for their use to regenerate, repair, and improve neural tissue, and to improve behavior and neurological function in stroke patients are disclosed.

Stem cells products having the potential to support cells of a soft tissue lineage, and methods of preparation and use of those stem cell products are disclosed. The invention also relates to methods for the use of such stem cells products in the regeneration and repair of soft tissue, and in cell-based therapies for of soft tissue conditions.

The invention concerns methods for automated culture of embryonic stem cells (ESCs) such as human ESCs. In some aspects, methods of the invention employ optimized culture media and limited proteolytic treatment of cells to separate cell clusters for expansion. Automated systems for passage and expansion of ESCs are also provided.

The present invention provides novel stem cell compositions having significant therapeutic and practical advantages, as well as methods of preparing and using such compositions for the treatment and prevention of injury and disease in patients. The invention may be applied to stem cell populations isolated from a wide variety of animals, including humans, and tissues. In particular applications, the invention is used to prepare a stem cell composition from a collagen-based tissue, such as adipose tissue, isolated from a patient, and the stem cell composition is subsequently provided to a site of actual or potential injury in the patient. The invention further includes related kits comprising the stem cell compositions, which are remarkably stable and retain viability and efficacy during storage and shipment.

The invention provides systems, modules, bioreactor and methods for the automated culture, proliferation, differentiation, production and maintenance of tissue engineered products. In one aspect is an automated tissue engineering system comprising a housing, at least one bioreactor supported by the housing, the bioreactor facilitating physiological cellular functions and/or the generation of one or more tissue constructs from cell and/or tissue sources. A fluid containment system is supported by the housing and is in fluid communication with the bioreactor. One or more sensors are associated with one or more of the housing, bioreactor or fluid containment system for monitoring parameters related to the physiological cellular functions and/or generation of tissue constructs; and a microprocessor linked to one or more of the sensors. The systems, methods and products of the invention find use in various clinical and laboratory settings.

Objects of the present invention are to provide a method for directly obtaining pluripotent stem cells from body tissue and the thus obtained pluripotent stem cells. The present invention relates to SSEA-3 (+) pluripotent stem cells that can be isolated from body tissue.

The invention discloses a method for culturing normal human lung tissue and a lung cancer tissue organoid in an in-vitro manner. The method includes: acquiring fresh human-derived lung tissue cells, and performing collagen digestion on the fresh human-derived lung tissue cells to obtain single cells; culturing human lung tissue and the lung cancer tissue organoid under in-vitro 3D culture conditions; performing H&E staining to determining the structure and form, and using q-PCR to detect related gene expression; using immunofluorescent staining to authenticate cell sources and detect related protein expression. The invention further discloses a method for building a mouse animal model based on the organoid. The method for culturing the normal human lung tissue and the lung cancer tissue organoid and the method for building the mouse animal model have the advantages that the methods are significant to the building of large-scale and good-consistency human-derived in-situ lung cancer animal models, and a good basis and related application prospect are provided for the fundamental researches of lung cancer.

The invention discloses a microfluidic chip and a cell screening method for screening specific cells. The chip comprises a substrate, a cavity and an acoustic excitation source, wherein the cavity comprises a middle channel, an inlet and an outlet; the acoustic excitation source is positioned on the substrate and at two sides of the middle channel and comprises two parts which extend to a direction of the outlet along the middle channel, wherein the corresponding acoustic resonance frequency of the second part close to the outlet is integer multiples of the corresponding acoustic resonance frequency of the first part far away from the outlet. Based on an acoustic streaming effect formed by targeted microbubbles and asymmetric sound fields, the microbubbles are adhered to the surfaces of the specific cells, so that the enriched cells which flow past the first part can still move in a straight line and cannot diffuse due to a laminar flow characteristic of microfluidics, and the specific cells bonded with the targeted microbubbles can shift because the acoustic resonance frequency of the second part is different from that of the first part. Thus, the screening of the specificity of the specific cells in blood is realized.

A method of generating cells predominantly displaying at least one characteristic associated with a cardiac phenotype is disclosed. The method comprises (a) partially dispersing a confluent cultured population of human stem cells, thereby generating a cell population including cell aggregates; (b) subjecting said cell aggregates to culturing conditions suitable for generating embryoid bodies; (c) subjecting said embryoid bodies to culturing conditions suitable for inducing cardiac lineage differentiation in at least a portion of the cells of said embryoid bodies, said culturing conditions suitable for inducing cardiac lineage differentiation including adherence of said embryoid bodies to a surface, and culture, medium supplemented with serum, thereby generating cells predominantly displaying at least one characteristic associated with a cardiac phenotype.

A biomedical material for transplant to a subject is provided according to embodiments of the present invention which includes an isolated donor tissue enzyme-treated to reduce the amount of proteoglycans in the donor tissue compared to untreated tissue. Isolated cells are optionally added to the enzyme-treated donor tissue, including leukocytes, particularly monocytes; macrophages; platelets; cells derived from an intervertebral disc such as chondrocyte-like nucleus pulposus cells; fibrocytes; fibroblasts; mesenchymal stem cells; mesenchymal precursor cells; chondrocytes; or a combination of any of these. The isolated donor tissue is articular cartilage or an intervertebral disc tissue such as nucleus pulposus tissue and/or annulus fibrosis tissue enzyme-treated to remove proteoglycans normally present in these tissues. A biomedical material of the present invention is administered to a subject to treat a disorder or injury, such as a disorder or injury to connective tissue.

There is disclosed a method of combining mesenchymal stem cells (MSCs) with a bone substrate. In an embodiment, the method includes obtaining tissue having MSCs together with unwanted cells. The tissue is digested to form a cell suspension having MSCs and unwanted cells. The cell suspension is added to the substrate. The substrate is cultured to allow the MSCs to adhere. The substrate is rinsed to remove unwanted cells. In various embodiments, the tissue is adipose issue, muscle tissue, or bone marrow tissue. In an embodiment, there is disclosed an allograft product including a combination of MSCs with a bone substrate in which the combination is manufactured by culturing MSCs disposed on the substrate for a period of time to allow the MSCs to adhere to the substrate, and then rinsing the substrate to remove unwanted cells from the substrate. Other embodiments are also disclosed.

The present invention provides improved methods for producing RPE cells from human embryonic stem cells or from other human pluripotent stem cells. The invention also relates to human retinal pigmented epithelial cells derived from human embryonic stem cells or other human multipotent or pluripotent stem cells. hRPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The hRPE cells described herein are useful for treating retinal degenerative diseases.

The invention discloses a method for efficiently separating single antigen-specific B lymphocyte from spleen cells. High-throughput rapid screening of single antigen-specific B lymphocyte is realizedby negative screening adopting multiple lymphocyte surface marker antibodies, establishment of a rapid fluorescence marked antigen substance method and high-specificity screening by use of a fluorescence marked antigen substance, and the positive rate of the finally obtained antibody-specific B lymphocyte is increased from less than 5% in a traditional hybridoma method to 30%. Therefore, the scheme can shorten monoclonal antibody development time to a great extent and greatly increase the number and diversity of obtained monoclonal antibodies.